All peptides offered by 1stPharma are produced through the lyophilization (freeze-drying) process, a method that preserves molecular stability during handling and transport for approximately 3–4 months. Once reconstituted with bacteriostatic water, the solution must be stored under refrigeration to maintain integrity, where it generally remains viable for up to 30 days. Lyophilization, also referred to as cryodesiccation, is a specialized dehydration technique in which the compound is frozen and then placed under reduced pressure. This causes the frozen water content to sublimate directly from solid ice to vapor, leaving behind a stable, crystalline peptide powder. The resulting white, porous material can be kept at room temperature until reconstitution is required. After delivery, peptides should be safeguarded from light exposure and stored in a cool environment. For short-term use spanning several days to weeks, refrigeration at or below 4°C (39°F) is recommended. While lyophilized peptides may remain structurally intact at room temperature for weeks, cold storage provides added assurance of stability for ongoing research. For extended preservation lasting months or years, ultra-low freezing is preferred. Storage at –80°C (–112°F) offers the most reliable option for maintaining peptide quality and consistency over long durations. For detailed guidance on peptide handling and storage protocols, please refer to: Peptide Storage Information – 1stPharma.com For extended preservation, particularly for storage spanning multiple months to years, peptides are best kept in ultra-low freezers at approximately –80°C (–112°F). Under these long-term conditions, structural stability is maximized, ensuring peptides retain their quality and suitability for future research applications.
What is GHRP-6?
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that functions as a potent stimulator of endogenous growth hormone release from the anterior pituitary. Classified as a ghrelin receptor (GHS-R1a) agonist, GHRP-6 belongs to a class of growth hormone secretagogues studied extensively for their ability to influence metabolic, neurologic, and regenerative pathways. Research indicates that GHRP-6 may impact cardiac tissue resilience, cognitive performance, wound healing, sexual motivation, and neuronal survival in models of neurodegeneration such as Parkinson’s disease. Unlike many peptides, GHRP-6 demonstrates activity via oral, sublingual, and parenteral administration routes, with moderate to high receptor selectivity.
GHRP-6 Structure
Sequence: His–D-Trp–Ala–Trp–D-Phe–Lys
Molecular Formula: C46H56N12O6
Molecular Weight: 873.03 g/mol
PubChem CID: 9919153
CAS Number: 87616-84-0
GHRP-6 Skeletal Structure — 1stPharma
GHRP-6 Research Highlights
1. Cognitive Function and Memory
Physical activity has long been associated with improved learning and memory retention. Recent investigations suggest that growth hormone secretagogues, including GHRP-6, may underlie these benefits. Rodent studies demonstrate that GHRP-6 facilitates the conversion of short-term memory into long-term storage and enhances performance in spatial learning tasks. These findings imply that growth hormone–mediated cognitive effects may in fact be driven by ghrelin receptor pathways activated by peptides such as GHRP-6.
2. Neuroprotection in Ischemia
Animal models of ischemic stroke have shown that GHRP-6 exerts protective effects on neurons and glial cells under conditions of reduced blood flow. Research indicates that timely administration may not only preserve brain tissue acutely but also mitigate post-stroke cognitive impairment. Mechanistic studies point to anti-apoptotic signaling and reduced neuroinflammation, suggesting that GHRP-6 enhances neuronal survival by blocking programmed cell death cascades and modulating the inflammatory microenvironment.
3. Protection of Dopaminergic Neurons in Parkinson’s Models
Research in 2018 identified functional ghrelin receptors in the substantia nigra, the brain region most affected by Parkinson’s disease. Genetic studies reveal that reduced receptor expression correlates with Parkinsonian pathology, while receptor blockade induces motor dysfunction in animal models. By acting as an agonist at these sites, GHRP-6 has been proposed to decrease dopaminergic neuron apoptosis, potentially slowing or delaying neurodegenerative processes associated with Parkinson’s disease.
4. Wound Healing, Collagen Formation, and Scar Modulation
GHRP-6 interacts with the CD36 receptor, promoting angiogenesis and cellular survival during wound repair. Experimental evidence in rodent models demonstrates accelerated wound closure, increased extracellular matrix protein synthesis (including collagen), and improved structural organization of healing tissue. Notably, GHRP-6 has been reported to reduce the formation of hypertrophic scars and keloids by preventing abnormal deposition of extracellular matrix proteins. This suggests potential utility in regulating scar appearance and enhancing tissue regeneration.
5. Cardiovascular Protection
Studies in porcine models of myocardial infarction show that GHRP-6 reduces oxidative damage to cardiac myocytes by limiting free radical–mediated cytotoxicity. This preservation of viable, yet vulnerable, heart tissue raises the possibility of therapeutic exploration in reducing infarct size and improving post-ischemic recovery. The peptide’s protective activity in cardiac tissue highlights its potential role in cardiovascular research models.
6. Modulation of Sexual Behavior and Mood
Ghrelin receptor signaling has been linked to sexual motivation and reward pathways in the central nervous system. Research in male rats suggests that stimulation of these receptors by GHRP-6 enhances sexual drive, while antagonism produces the opposite effect. Beyond reproductive behavior, ghrelin receptor activity has been associated with mood regulation. Preclinical studies in mice indicate that GHRP-6 reduces depressive-like behaviors and improves stress resilience, underscoring its potential role in mood and affective disorder research.
Safety and Research Use
GHRP-6 exhibits favorable subcutaneous bioavailability in animal studies and minimal reported adverse effects in preclinical models. Oral and sublingual routes have demonstrated partial activity. It is important to note that all GHRP-6 supplied by 1stPharma is exclusively intended for laboratory research. This compound is not a pharmaceutical drug, dietary supplement, or therapeutic product. It has not been evaluated by the FDA or other regulatory agencies for human or veterinary use. Any application outside controlled laboratory research, including bodily administration, is strictly prohibited.
Referenced Citations
- Huang, C-C., Chou, D., Yeh, C-M., & Hsu, K-S. (2016). Ghrelin signaling and fear extinction in the amygdala. Neuropharmacology, 101, 36–45.
- Beheshti, S., & Shahrokhi, S. (2015). Ghrelin receptor blockade impairs memory encoding in rats. Neuropeptides, 52, 97–102.
- Tóth, K., László, K., & Lénárd, L. (2010). Ghrelin in spatial learning. Brain Research Bulletin, 81(1), 33–37.
- Subirós, N., et al. (2016). Therapeutic window of rhEGF and GHRP-6 in stroke models. Neurological Research, 38(3), 187–195.
- Spencer, S. J., Miller, A. A., & Andrews, Z. B. (2013). Ghrelin in neuroprotection post-ischemia. Brain Sciences, 3(1), 344–359.
- Suda, Y., et al. (2018). Ghrelin receptor down-regulation and Parkinson’s pathology. Molecular Brain, 11(1), 6.
- Mendoza MarÃ, Y., et al. (2016). GHRP-6 and wound healing outcomes. Plastic Surgery International.
- Fernández-Mayola, M., et al. (2018). GHRP-6 prevents hypertrophic scarring. International Wound Journal, 15(4), 538–546.
- Berlanga, J., et al. (2007). GHRP-6 reduces myocardial necrosis in acute infarction. Clinical Science, 112(4), 241–250.
- Hyland, L., et al. (2018). Ghrelin receptor stimulation and sexual motivation. Hormones and Behavior, 97, 56–66.
- Huang, H-J., et al. (2019). Ghrelin/GHSR neuroprotection in hippocampal models. Neuropharmacology.
- Korbonits, M., & Grossman, A. B. (1995). Growth hormone-releasing peptide and analogues. Trends in Endocrinology & Metabolism, 6(2), 43–49.
| Packing |
10mg |
|---|
Reviews
There are no reviews yet.